<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111305</url>
  </required_header>
  <id_info>
    <org_study_id>10-I-0101</org_study_id>
    <secondary_id>100101</secondary_id>
    <nct_id>NCT01111305</nct_id>
  </id_info>
  <brief_title>Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the
      development of severe adverse reactions that are correlated with the number of circulating
      microfilariae in the blood. The cause of these reactions is unknown, but they are accompanied
      by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of
      eosinophil activation. This randomized, placebo-controlled, double-blind pilot study
      (conducted at the NIH Clinical Center) will assess whether and to what extent the
      administration of reslizumab (Cinquil ), a humanized monoclonal antibody directed against
      IL-5, given 3 to 7 days before administration of the anthelminthic drug DEC (at 3 mg/kg 3
      times daily for 21 days), prevents the development of eosinophilia in 10 adult subjects with
      Loa loa infection and 0-5000 microfilariae/mL. Secondary outcomes will include the severity
      of post-treatment effects, markers of eosinophil activation, and effects of reslizumab on
      microfilarial clearance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Loa loa is a parasitic worm that infects people in West and Central Africa and is spread by
      the bite of a deerfly. Adult worms (macrofilariae) live under the skin and cause symptoms
      such as swellings, itching, and hives. Smaller worms (microfilariae) are found in the
      bloodstream. Diethylcarbamazine (DEC), the recommended medication for Loa loa infection, can
      produce very serious side effects, especially in people with high numbers of parasites in the
      blood. Researchers are investigating new treatments for Loa loa that have fewer or less
      serious side effects. Researchers believe that a certain kind of blood cells called
      eosinophils, which increase in the blood after DEC treatment, may be one of the causes of the
      side effects seen with DEC treatment. Reslizumab is a drug that lowers eosinophils in the
      blood. Giving reslizumab before DEC treatment might prevent the eosinophils from increasing
      and reduce some of the side effects from DEC.

      Objectives:

      - To determine whether reslizumab can prevent or reduce the side effects of treatment with
      DEC for Loa loa infection.

      Eligibility:

      Screening: Individuals between 18 and 65 years of age who have lived in or traveled to a
      Loa-endemic region for at least 1 month

      Treatment study: Individuals with Loa loa infection and low numbers of parasites in the blood

      Design:

      This study will last 24 months and will involve several visits to the National Institutes of
      Health Clinical Center. Participants will be screened with a blood test for Loa loa
      parasites. Those who have a low number of Loa loa parasites in the blood will be asked to
      return for a full medical evaluation and the start of the treatment phase. Those who do not
      have Loa loa parasites in the blood, or those who have a high number of Loa loa parasites in
      the blood, are not eligible for this study treatment but may be eligible for other parasitic
      disease studies conducted by the National Institutes of Health.

      Participants will have an initial visit with a full physical evaluation, and blood and urine
      tests (including leukapheresis to provide sufficient numbers of blood cells for testing).
      Within 1 month of the first visit, participants will have a single infusion of either
      reslizumab or a placebo. The infusion visit is estimated to last approximately 5 hours. Three
      to 7 days after the infusion, participants will begin a 21-day course of DEC (taken by mouth)
      to treat the infection. Participants will stay overnight at the Clinical Center during the
      first 3 days of treatment with DEC to be monitored for side effects, and will continue to
      take the DEC at home after the inpatient treatment. A study coordinator will call
      participants each day to ask about any symptoms or side effects. Participants will be seen
      for an additional eight outpatient follow-up visits (at days 7, 14, and 28, and months 3, 6,
      12, 18, and 24) for evaluation of signs and symptoms of infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Drug assignment (reslizumab vs. placebo) and eosinophil count</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Peak Eosinophil Count Measure as a Percent of Baseline Count.</measure>
    <time_frame>during the first 7 days of DEC treatment</time_frame>
    <description>Peak eosinophil count during the first 7 days of treatment as a percent of the baseline count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE's</measure>
    <time_frame>7 days following initiation of DEC treatment</time_frame>
    <description>Adverse events during the first week of DEC treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Eosinophil Activation Including Levels of Eosinophil Surface Marker Expression and Serum Levels of Eosinophil Granule Proteins</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Clear Blood Microfilariae</measure>
    <time_frame>3, 7, and 28 days after initiation of treatment with DEC</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Loiasis</condition>
  <arm_group>
    <arm_group_label>Reslizumab + DEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + DEC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reslizumab</intervention_name>
    <arm_group_label>Reslizumab + DEC</arm_group_label>
    <other_name>Cinqair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylcarbamazine</intervention_name>
    <arm_group_label>Reslizumab + DEC</arm_group_label>
    <arm_group_label>Placebo + DEC</arm_group_label>
    <other_name>Hetrazan, Banocide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + DEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA: (Screening)

        A subject will be eligible for participation in the screening portion of this protocol if
        all of the following criteria apply:

          1. Between 18 and 65 years of age

          2. Residence in or travel to a Loa-endemic region for greater than 1 month

        EXCLUSION CRITERIA: (Screening)

        A subject will not be eligible for participation in the screening portion of this study if
        any of the following conditions apply:

          1. Known to be pregnant

          2. Known to be HIV-positive

        INCLUSION CRITERIA: (Interventional Study)

        A subject will be eligible for participation in the interventional portion of the study
        only if all of the following criteria apply:

          1. The subject has documented loiasis with 0-5000 microfilariae/mL blood.

          2. The subject agrees to storage of samples for study

          3. A female subject is eligible for this study if she is any of the following:

               -  Not pregnant or breast-feeding.

               -  Of non-childbearing potential (i.e., women who have had a hysterectomy or tubal
                  ligation or are post-menopausal, as defined by no menses in greater than or equal
                  to 1 year)

               -  Of childbearing potential but agrees to practice effective contraception* or
                  abstinence for 3 months after administration of the investigational study drug
                  (reslizumab or placebo)

                    -  NOTE: Acceptable methods of contraception may include one or more of the
                       following: 1) male partner who is sterile prior to the female subject s
                       entry into the study and is the sole sexual partner for the female subject;
                       2) implants of levonorgestrel; 3) injectable progestogen, an intrauterine
                       device with a documented failure rate of less than 1percent; 4) oral
                       contraceptives; and 5) double barrier methods including diaphragm or condom
                       with a spermicide.

        EXCLUSION CRITERIA: (Interventional Study)

        A subject will not be eligible to participate in the interventional portion of the study if
        any of the following conditions are fulfilled at the time of enrollment:

          1. The subject tests positive for HIV infection or has any other known immunodeficiency.

          2. The subject has a concomitant active infection with Onchocerca volvulus.

          3. The subject has used any other investigational agent within the past 30 days.

          4. The subject has used immunosuppressive agents (as listed in section 8.1) within the
             past 30 days.

          5. The subject has a history of allergic reaction to any antibody therapy or to DEC.

          6. The subject has chronic kidney or liver disease.

          7. The subject has any condition that, in the Investigator s opinion, places the subject
             at undue risk by participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy D Klion, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2010-I-0101.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Limaye AP, Abrams JS, Silver JE, Ottesen EA, Nutman TB. Regulation of parasite-induced eosinophilia: selectively increased interleukin 5 production in helminth-infected patients. J Exp Med. 1990 Jul 1;172(1):399-402.</citation>
    <PMID>2193099</PMID>
  </reference>
  <reference>
    <citation>Klion AD, Massougbodji A, Sadeler BC, Ottesen EA, Nutman TB. Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. J Infect Dis. 1991 Jun;163(6):1318-25.</citation>
    <PMID>2037798</PMID>
  </reference>
  <reference>
    <citation>Klion AD, Ottesen EA, Nutman TB. Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. J Infect Dis. 1994 Mar;169(3):604-10.</citation>
    <PMID>8158033</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2010</study_first_submitted>
  <study_first_submitted_qc>April 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <results_first_submitted>April 27, 2017</results_first_submitted>
  <results_first_submitted_qc>April 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2017</results_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Filariasis</keyword>
  <keyword>Post-Treatment Reactions</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Loa Loa</keyword>
  <keyword>Loiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eosinophilia</mesh_term>
    <mesh_term>Loiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reslizumab</mesh_term>
    <mesh_term>Diethylcarbamazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>31 subjects were enrolled on the screening phase of this protocol, of which 13 had Loa loa infection. Of these 13, 3 were excluded for Loa loa microfilarial loads that were too high, 1 could not comply with the trial time points, and one was lost to followup. This left 8 subjects who were enrolled on the treatment portion of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Reslizumab</title>
          <description>Reslizumab
Diethylcarbamazine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Diethylcarbamazine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Reslizumab</title>
          <description>Reslizumab
Diethylcarbamazine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Diethylcarbamazine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" lower_limit="22" upper_limit="44"/>
                    <measurement group_id="B2" value="29" lower_limit="20" upper_limit="55"/>
                    <measurement group_id="B3" value="31.5" lower_limit="20" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Loa loa microfilarial level</title>
          <units>mf/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212" lower_limit="0" upper_limit="2120"/>
                    <measurement group_id="B2" value="357" lower_limit="178" upper_limit="810"/>
                    <measurement group_id="B3" value="275" lower_limit="0" upper_limit="2120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Absolute eosinophil count</title>
          <units>cells/microliter</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1350" lower_limit="530" upper_limit="3130"/>
                    <measurement group_id="B2" value="710" lower_limit="560" upper_limit="1590"/>
                    <measurement group_id="B3" value="980" lower_limit="530" upper_limit="3130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Peak Eosinophil Count Measure as a Percent of Baseline Count.</title>
        <description>Peak eosinophil count during the first 7 days of treatment as a percent of the baseline count</description>
        <time_frame>during the first 7 days of DEC treatment</time_frame>
        <population>Subjects who received diethylcarbamazine treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Reslizumab + DEC</title>
            <description>Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
Reslizumab
Diethylcarbamazine</description>
          </group>
          <group group_id="O2">
            <title>Placebo + DEC</title>
            <description>Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
Diethylcarbamazine
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Eosinophil Count Measure as a Percent of Baseline Count.</title>
          <description>Peak eosinophil count during the first 7 days of treatment as a percent of the baseline count</description>
          <population>Subjects who received diethylcarbamazine treatment</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="42.7" upper_limit="104"/>
                    <measurement group_id="O2" value="245.6" lower_limit="175" upper_limit="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence is defined as pâ‰¥0.05</non_inferiority_desc>
            <p_value>0.028</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of AE's</title>
        <description>Adverse events during the first week of DEC treatment</description>
        <time_frame>7 days following initiation of DEC treatment</time_frame>
        <population>Subjects who received DEC treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Reslizumab + DEC</title>
            <description>Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
Reslizumab
Diethylcarbamazine</description>
          </group>
          <group group_id="O2">
            <title>Placebo + DEC</title>
            <description>Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
Diethylcarbamazine
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of AE's</title>
          <description>Adverse events during the first week of DEC treatment</description>
          <population>Subjects who received DEC treatment</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Eosinophil Activation Including Levels of Eosinophil Surface Marker Expression and Serum Levels of Eosinophil Granule Proteins</title>
        <time_frame>two years</time_frame>
        <posting_date>12/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Clear Blood Microfilariae</title>
        <time_frame>3, 7, and 28 days after initiation of treatment with DEC</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reslizumab</title>
            <description>Reslizumab
Diethylcarbamazine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Diethylcarbamazine</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Clear Blood Microfilariae</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <desc>A standardized questionnaire was used to record symptoms at every visit. Laboratory assessments were performed at every visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Reslizumab + DEC</title>
          <description>Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
Reslizumab
Diethylcarbamazine</description>
        </group>
        <group group_id="E2">
          <title>Placebo + DEC</title>
          <description>Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
Diethylcarbamazine
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LDH increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Calabar swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Amy Klion</name_or_title>
      <organization>NIAID/NIH</organization>
      <phone>301-435-8903</phone>
      <email>aklion@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

